Post-Induction Consolidation With Blinatumomab vs Chemotherapy in First-Relapse B-Cell Acute Lymphoblastic Leukemia: Evidence From Randomized Controlled Trials (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-1212; Location: LEVEL 3, HALL B3; "Blinatumomab demonstrated superior survival outcomes and increased the likelihood of patients proceeding to HSCT. These findings support its use as an effective postinduction consolidation strategy in pediatric and young adult patients with relapsed B-ALL. BALL: B-cell acute lymphoblastic leukemia, CI: confidence interval, CD: cluster of differentiation, DFS: disease-free survival, HR: hazard ratio, HSCT: hematopoietic stem cell transplantation, OS: overall survival, PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses."
Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Bashar M Al Zoubi MD 1; Abdullah H Alshurafa MD 2; Saleh Al-Hadid MD 1; Ahmad Hudaib MD 1; Sara Shaban MD 1; Zeena B Okoor MD 1; Bara'a Alrefaie MD 1
|